secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortrea Holdings Inc. (FTRE)
CIK:        0001965040
Form:       8-K
Filed at:   2023-11-29T23:59:59+00:00
Accession:  0001965040-23-000048
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortrea disputes ACELYRIN claims on HS and PsA trial conduct; stands by data integrity
--------------------------------------------------------------------------------

- Fortrea objects to ACELYRIN's implication that its conduct of the Hidradenitis Suppurativa trial impacted outcomes.
- Disputes accuracy of statements about testing processes and who uncovered the third-party programming error in Psoriatic Arthritis trial.
- Sequencing issue isolated to two arms of the PsA trial, unrelated to the HS trial; no patient safety risk per ACELYRIN.
- Third-party programmer not endpoint Clinical (affiliated with Fortrea); cannot be named due to contractual commitments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1965040/000196504023000048/0001965040-23-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1965040/000196504023000048/ftre-20231127.htm
  HTML page:      https://secwatch.observer/filing/0001965040-23-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer